Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
-
Comparative Study
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
Routine influenza vaccination is currently recommended in several countries for people aged more than 60 or 65 years or with high risk of complications. A lower age threshold of 50 years has been recommended in the United States since 1999. To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy. ⋯ Extending routine influenza vaccination to people more than 50 years of age is likely to be cost-effective in all four countries studied.